Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AKO 002

Next Previous
X
Search
Drug Profile

AKO 002

Alternative Names: AKO-002; Psilocybin-based formulation - Akome Biotech

Latest Information Update: 08 Mar 2022

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Akome Biotech
  • Developer Akome Biotech; Complutense University Madrid
  • Class Antidementias; Dimethylamines; Indoles; Neuropsychotherapeutics; Organophosphorus compounds; Phytotherapies; Small molecules
  • Mechanism of Action Amyloid beta-protein inhibitors; ATP-binding cassette transporter modulators; Serotonin 5-HT2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease

Most Recent Events

  • 04 Mar 2022 Akome Biotech and Universidad Complutense de Madrid agree to co-develop psychedelic compounds for the treatment of Alzheimer's disease, Parkinson's disease, major depressive disorder and ischaemic stroke
  • 04 Mar 2022 Preclinical trials in Alzheimer's disease in Spain and Canada
  • 06 May 2021 Early research in Alzheimer's disease in Canada (unspecified route)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top